Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label single-arm study of VG161 in advanced intrahepatic cholangiocarcinoma
CTR20213020Phase 2Active
- Sponsor
- Sinopharm CNBG-Virogin Biotech
- Start
- May 2022
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of VG161 in intrahepatic cholangiocarcinoma (ICC), sponsored by Sinopharm CNBG-Virogin Biotech. Started May 2022; status: active.
02
Drugs
VG161
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on CTR20213020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213020.